This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
In people suspected of having HHC, the two strategies were liver biopsy versus DNA testing in a hypothetical 45-yearold man. In siblings and offspring of people diagnosed with HCC, the two strategies were biochemical testing versus DNA testing. Biochemical tests consisted of transferring saturation (TS) and serum ferritin (SF). Those patients with TS over 45% and SF over 300μg/L were treated, while the remaining patients were monitored to see if the iron level increased.
Location/setting
UK/clinical laboratory.
Methods

Analytical approach:
This economic evaluation was based on two decision analytic models with a short time horizon, which was the testing and treatment period. In one model, individuals suspected of having haemochromatosis were analysed and, in the other, family members of those diagnosed with haemochromatosis were analysed. The authors stated that the perspective was that of the National Health Service (NHS).
Effectiveness data:
The clinical data were collected from systematic reviews and systematic searches supplemented by expert opinions. The design and other characteristics of the primary studies were not reported, except for a few studies. UK studies were selected, when available, and non-UK sources were adapted to the local context by means of expert opinions. The key clinical endpoint was the accuracy of the strategies.
Monetary benefit and utility valuations:
None.
Measure of benefit:
The summary benefit measure was the number of cases detected.
Results
The efficacy of the relevant strategies was similar in all simulations. The number of cases detected per 100 people tested was 75.1 with both strategies for people suspected of having HCC, 19 with both strategies in the sibling model, and 3.5 with both strategies in the offspring model.
In the simulation of 100 people suspected of having HCC, the total cost was £83,068 with liver biopsy and £73,823 with DNA testing. Thus, DNA testing saved £92.5 per person tested in comparison with liver biopsy.
In the model of 100 siblings, the total cost was £23,628 with the biochemical test and £27,423 with DNA testing. Thus, DNA testing resulted in an incremental cost per case detected of £200 compared with the biochemical test.
In the model of 100 offspring, the total cost was £46,753 with the biochemical test and £18,638 with DNA testing. Thus, DNA testing saved £7,982 per case detected in comparison with the biochemical test.
The results of the sensitivity analysis confirmed that the base-case findings were robust. The most influential model inputs in the primary simulation were the proportion of patients with a positive DNA test for the C282Y mutation, the specificity of the TS test, and the cost of liver biopsy. For siblings, the most influential inputs were the cost of the DNA test and the cost of monitoring. A reduction of 40% in the cost of the DNA test or if those who were monitored were retested twice (instead of once) would make this strategy cost-saving. For offspring, the key inputs were the number of times the offspring were monitored and the penetrance of disease.
The probabilistic sensitivity analysis changed the magnitude of savings or additional costs, but did not alter the basecase findings.
